523 related articles for article (PubMed ID: 29538686)
1. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
2. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
3. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
4. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
[TBL] [Abstract][Full Text] [Related]
6. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
[TBL] [Abstract][Full Text] [Related]
8. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
Zeng Z; Zhao H; Dorr MB; Shen J; Wilcox MH; Poxton IR; Guris D; Li J; Shaw PM
Anaerobe; 2020 Feb; 61():102137. PubMed ID: 31846705
[TBL] [Abstract][Full Text] [Related]
9. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
[TBL] [Abstract][Full Text] [Related]
10. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
[TBL] [Abstract][Full Text] [Related]
12. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
13. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
Villafuerte Gálvez JA; Kelly CP
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
[TBL] [Abstract][Full Text] [Related]
14. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
Deeks ED
Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
[TBL] [Abstract][Full Text] [Related]
15. Recurrent
Song JH; Kim YS
Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
[TBL] [Abstract][Full Text] [Related]
18. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent
Yee KL; Kleijn HJ; Kerbusch T; Matthews RP; Dorr MB; Garey KW; Wrishko RE
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455246
[TBL] [Abstract][Full Text] [Related]
20.
Asempa TE; Nicolau DP
Clin Interv Aging; 2017; 12():1799-1809. PubMed ID: 29123385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]